Treatment of p-ANCA Lung Disease

Initial Assessment and Risk Stratification

The American College of Physicians recommends determining whether the patient has isolated lung involvement or systemic ANCA-associated vasculitis with pulmonary manifestations, and assessing for pulmonary hemorrhage or interstitial lung disease patterns on imaging, as this information affects treatment decisions 1, 4
Renal involvement should be assessed, as it affects plasma exchange decisions, with the American Society of Nephrology recommending checking creatinine and urinalysis for hematuria or proteinuria 1, 2

The European Respiratory Society recommends using a reduced-dose glucocorticoid regimen, rather than traditional high-dose protocols, as recent evidence shows equivalent efficacy with fewer adverse effects 1, 2
The American College of Rheumatology recommends choosing between rituximab or cyclophosphamide based on the patient's specific condition, with rituximab preferred for relapsing disease and cyclophosphamide for severe, life-threatening disease 2, 5

The American Thoracic Society recommends against using plasma exchange for pulmonary hemorrhage without renal involvement, as the evidence shows little effect on mortality and increased risk of serious infection 1, 2
Plasma exchange should only be used if the patient has severe renal involvement, requires dialysis, or has rapidly increasing creatinine, with the National Kidney Foundation recommending careful consideration of the risks and benefits 5, 3

The Infectious Diseases Society of America recommends pneumocystis jirovecii prophylaxis with trimethoprim/sulfamethoxazole for all patients receiving cyclophosphamide, as well as MESNA to prevent hemorrhagic cystitis 5, 3
Regular monitoring of blood counts, renal function, urinalysis, and inflammatory markers is recommended, with the American Society of Nephrology suggesting close monitoring to adjust treatment as needed 3, 4

The European League Against Rheumatism recommends transitioning to maintenance therapy after achieving remission, with rituximab preferred for MPO-ANCA and all relapsing disease, and azathioprine as an alternative if rituximab is unavailable 4, 6
The American College of Rheumatology recommends continuing maintenance therapy for 18 months to 4 years after achieving complete remission, with regular monitoring to adjust treatment as needed 5

The American College of Rheumatology recommends restarting glucocorticoids combined with rituximab or cyclophosphamide for major relapse, with rituximab preferred for relapsing disease 3
For treatment-resistant disease, the European Respiratory Society recommends considering switching from cyclophosphamide to rituximab or vice versa, evaluating for combination therapy, and reassessing diagnosis to exclude alternative causes 4, 6